Suppr超能文献

三维可视化技术在原发性肝癌精准诊疗中的疗效:中国1665例回顾性多中心研究

[Efficacy of three-dimensional visualization technology in the precision diagnosis and treatment for primary liver cancer: a retrospective multicenter study of 1 665 cases in China].

作者信息

Fang C H, Zhang P, Zhou W P, Zhou J, Dai C L, Liu J F, Jia W D, Liang X, Zeng S L, Wen S

机构信息

First Department of Hepatobiliary Surgery, Zhujiang Hospital, Southern Medical University, Guangdong Provincial Clinical and Engineering Center of Digital Medicine, Guangzhou 510282, China.

Third Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Affiliated to Naval Medical University, Shanghai 200433, China.

出版信息

Zhonghua Wai Ke Za Zhi. 2020 May 1;58(5):375-382. doi: 10.3760/cma.j.cn112139-20200220-00105.

Abstract

To evaluate the efficacy of three-dimensional(3D) visualization technology in the precision diagnosis and treatment for primary liver cancer. A total of 1 665 patients with primary liver cancer who admitted to seven medical centers in China between January 2009 to January 2019, diagnosed and treated by 3D visualization protocol were analyzed, and their clinical data were retrospectively reviewed. There were 1 255 males(75.4%) and 410 females(24.6%), with age of (52.9±11.9) years (range: 18 to 86 years). The acquisition of high-quality CT images with submillimeter spatial resolution were conducted using a quality control system. By means of homogenization methods, 3D reconstruction and 3D visualization analysis were performed. Postoperative observation: pathology reports, microvascular invasion, perioperative complications and follow-up. SPSS 25.0 statistical software was used for statistical description and analysis of clinical data. Kaplan-Meier curve was used to calculate overall survival and disease-free survival rate. (1)In the sample of 1 265 patients, 3D reconstructed models clearly displayed as follows. tumor size: ≤2 cm in 155 cases (9.31%), >2 cm to 5 cm in 551 cases (33.09%), >5 cm to 10 cm in 636 cases (38.20%), >10 cm in 323 cases (19.40%). (2) Classification of hepatic blood vessels. Hepatic artery: type Ⅰ(normal type) in 1 494 cases(89.73%),variant hepatic artery in 171 cases (10.27%), including type Ⅱ in 35 cases, type Ⅲ in 38 cases, and other types in 98 cases. Hepatic vein: type Ⅰ (normal) in 1 195 cases (71.77%),variant hepatic veins in 470 cases(28.23%), including type Ⅱ in 376 cases and type Ⅲ in 94 cases. Portal vein:normal type in 1 315 cases (78.98%), variant portal veins in 350 cases (21.02%), including type Ⅰ in 189 cases, type Ⅱin 103 cases, type Ⅲ in 50 cases, type Ⅳ in 8 cases. Hepatic artery variation coexisting with portal vein variation in 24 cases (1.44%). Hepatic vein variation coexisting with portal vein variation in 113 cases (6.79%). Three types of vascular variation in 4 cases (0.24%), including coexistence of type Ⅱ hepatic artery variation or type Ⅰ portal vein variation with type Ⅲ hepatic vein variation in 2 cases,coexistence of type Ⅲ hepatic artery variation or type Ⅲ portal vein variation with type Ⅱ hepatic vein variation in 2 cases. (3) Preoperative liver volume calculation:1 499.3 (514.4)ml (range:641.7 to 6 637.0 ml) of total liver volume, including 479.1 (460.1) ml (range:10.5 to 2 086.8 ml) for liver resection and 959.9 (460.4)ml (range:306.1 to 5 638.0 ml) for residual function. (4)Operative methods: anatomical hepatectomy in 1 458 cases (87.57%); non-anatomic hepatectomy in 207 cases (12.43%). (5)the median operation time was 285(165)minutes (range: 40 to720 minutes). (6)The median intraoperative blood loss was 200(250)ml (range:10 to 4 200 ml) and 346 cases (20.78%) had intraoperative transfusion. (7)Pathology reports: hepatocellular carcinoma in 1 371 cases (82.34%), cholangiocarcinoma in 260 cases (15.62%) and mixed hepatocellular carcinoma in 34 cases (2.04%). Microvascular invasion: M0 in 199 cases, M1 in 64 cases, and M2 in 27 cases. (8)Postoperative complications in 207 cases (12.43%), including Clavien-Dindo grade Ⅰ or Ⅱ in 57 cases, grade Ⅲ or Ⅳ in 147 cases and grade Ⅴ in 3 cases.There were 13 cases (0.78%) of liver failure and 3 cases (0.18%) of perioperative death. (9) The follow-up time was 3.0 to 96.0 months, with a median time of 21.0(17.8) years. The overall 3-year survival and disease-free survival rates were 80.0% and 56.5%, respectively. The overall 5-year survival and disease-free survival rates were 59.7% and 30.0%, respectively. 3D visualization technology plays an important role in realizing accurate diagnosis of anatomical location and morphology of primary liver cancer, improving the success rate of surgery and reducing the incidence of complications.

摘要

评估三维(3D)可视化技术在原发性肝癌精准诊断和治疗中的疗效。分析了2009年1月至2019年1月在中国7个医疗中心收治的1665例原发性肝癌患者,这些患者均采用3D可视化方案进行诊断和治疗,并对其临床资料进行回顾性分析。其中男性1255例(75.4%),女性410例(24.6%),年龄为(52.9±11.9)岁(范围:18至86岁)。使用质量控制系统获取具有亚毫米空间分辨率的高质量CT图像。通过同质化方法进行3D重建和3D可视化分析。术后观察指标包括:病理报告、微血管侵犯、围手术期并发症及随访情况。采用SPSS 25.0统计软件对临床资料进行统计描述和分析。采用Kaplan-Meier曲线计算总生存率和无病生存率。(1)在1265例患者样本中,3D重建模型清晰显示如下:肿瘤大小:≤2cm的有155例(9.31%),>2cm至5cm的有551例(33.09%),>5cm至10cm的有636例(38.20%),>10cm的有323例(19.40%)。(2)肝血管分类。肝动脉:Ⅰ型(正常型)1494例(89.73%),肝动脉变异171例(10.27%),其中Ⅱ型35例,Ⅲ型38例,其他类型98例。肝静脉:Ⅰ型(正常)1195例(71.77%),肝静脉变异470例(28.23%),其中Ⅱ型376例,Ⅲ型94例。门静脉:正常型1315例(78.98%),门静脉变异350例(21.02%),其中Ⅰ型189例,Ⅱ型103例,Ⅲ型50例,Ⅳ型8例。肝动脉变异与门静脉变异共存24例(1.44%)。肝静脉变异与门静脉变异共存113例(6.79%)。三种血管变异共存4例(0.24%),其中Ⅱ型肝动脉变异或Ⅰ型门静脉变异与Ⅲ型肝静脉变异共存2例,Ⅲ型肝动脉变异或Ⅲ型门静脉变异与Ⅱ型肝静脉变异共存2例。(3)术前肝脏体积计算:全肝体积为1499.3(514.4)ml(范围:641.7至6637.0ml),其中肝切除体积为479.1(460.1)ml(范围:10.5至2086.8ml),残余功能体积为959.9(460.4)ml(范围:306.1至5638.0ml)。(4)手术方式:解剖性肝切除1458例(87.57%);非解剖性肝切除207例(12.43%)。(5)中位手术时间为285(165)分钟(范围:40至720分钟)。(6)中位术中出血量为200(250)ml(范围:10至4200ml),346例(20.78%)患者术中输血。(7)病理报告:肝细胞癌1371例(82.34%),胆管癌260例(15.62%),混合性肝细胞癌34例(2.04%)。微血管侵犯情况:M0为199例,M1为64例,M2为27例。(8)术后并发症207例(12.43%),其中Clavien-DindoⅠ级或Ⅱ级57例,Ⅲ级或Ⅳ级147例,Ⅴ级3例。肝衰竭13例(0.78%),围手术期死亡3例(0.18%)。(9)随访时间为3.0至96.0个月,中位时间为21.0(17.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验